I-Mab (IMAB) CEO Management on Q4 2021 Results - Earnings Call Transcript

I-Mab (NASDAQ:IMAB) Q4 2021 Earnings Conference Call March 29, 2022 8:00 AM ET

Company Participants

Tyler Ehler - Senior Director of Investor Relations
Jingwu Zang - Founder, Chairman and Acting CEO
Andrew Zhu - President
John Long - Chief Financial Officer
Jielun Zhu - Chief Strategy Officer

Conference Call Participants

Kelly Shi - Jefferies
Louise Chen - Cantor
Joe Catanzaro - Piper
Andres Maldonado - HCW

Operator

Tyler Ehler

Good morning, ladies and gentlemen. Thank you all for standing by. And I'd like to welcome you all to the I-Mab Biopharma Full Year 2021 Financial Results and Business Update Conference Call. This is Tyler Ehler, I-Mab's Senior Director of Investor Relations. At this time, all participants are in a listen-only mode. Later, we'll conduct a Q&A session and instructions will follow at that time.

Earlier today, we issued a press release providing a review of our financial results for the full year ended December 31, 2021, as well as an overview of our recent corporate highlights and upcoming milestones. The press release can be accessed on the Investors portion of our website at ir.i-mabbiopharma.com.

Joining me today on the call from I-Mab senior management team are Dr. Jingwu Zang, our Founder, Chairman and Acting CEO of I-Mab, Dr. Andrew Zhu, our President of I-Mab, Mr. John Long, CFO of I-Mab and Mr. Jielun Zhu, Chief Strategy Officer of I-Mab. Dr. Zhang will start by providing a high level overview of our recent achievements and upcoming milestones, followed by Dr. Andrew Zhu, who will provide an update on our R&D progress, and Mr. Zhu, who will provide an update on our commercialization capabilities. Mr. Long will then provide a summary of our financial results for the full year ended December 31, 2021 before we turn the call to the operator to take your questions.